Skip to content
naulon

No retraction, correction or concern found when last checked on Oct 27, 2026.

Recent Applications of Liposomes in Ophthalmic Drug Delivery

Gyan P. Mishra, Mahuya Bagui, Viral Tamboli and 1 more

Journal of Drug Delivery · 2011 · Review

doi:10.1155/2011/863734

Abstract

Liposomal formulations were significantly explored over the last decade for the ophthalmic drug delivery applications. These formulations are mainly composed of phosphatidylcholine (PC) and other constituents such as cholesterol and lipid-conjugated hydrophilic polymers. Liposomes are biodegradable and biocompatible in nature. Current approaches for topical delivery of liposomes are focused on improving the corneal adhesion and permeation by incorporating various bioadhesive and penetration enhancing polymers. In the case of posterior segment disorders improvement in intravitreal half life and targeted drug delivery to the retina is achieved by liposomes. In this paper we have attempted to summarize the applications of liposomes in the field of ophthalmic drug delivery by citing numerous investigators over the last decade.

References 82

  1. 1.

    Geroski DH, Edelhauser HF. Drug delivery for posterior segment eye disease. Investigative Ophthalmology and Visual Science. 2000;41(5):961-964.

    Not in our library

  2. 2.

    Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Advanced Drug Delivery Reviews. 2006;58(11):1131-1135.

    Not in our library10.1016/j.addr.2006.07.027

  3. 3.

    Mitra AK. Role of transporters in ocular drug delivery system. Pharmaceutical Research. 2009;26(5):1192-1196.

    Not in our library10.1007/s11095-009-9862-x

  4. 4.

    Kaur IP, Kanwar M. Ocular preparations: the formulation approach. Drug Development and Industrial Pharmacy. 2002;28(5):473-493.

    Not in our library10.1081/ddc-120003445

  5. 5.

    Wadhwa S, Paliwal R, Vyas SP. Nanocarriers in ocular drug delivery: an update review. Current Pharmaceutical Design. 2009;15(23):2724-2750.

    Not in our library10.2174/138161209788923886

  6. 6.

    Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. Journal of Molecular Biology. 1965;13(1):238-252.

    Not in our library10.1016/s0022-2836(65)80093-6

  7. 7.

    Kaur IP, Garg A, Singla AK, Aggarwal D. Vesicular systems in ocular drug delivery: an overview. International Journal of Pharmaceutics. 2004;269(1):1-14.

    Not in our library10.1016/j.ijpharm.2003.09.016

  8. 8.

    Mainardes RM, Urban MCC, Cinto PO, et al. Colloidal carriers for ophthalmic drug delivery. Current Drug Targets. 2005;6(3):363-371.

    Not in our library10.2174/1389450053765914

  9. 9.

    Elbayoumi TA, Torchilin VP. Current trends in liposome research. Methods in Molecular Biology. 2010;605:1-27.

    Not in our library10.1007/978-1-60327-360-2_1

  10. 10.

    Li N, Zhuang C, Wang M, Sun X, Nie S, Pan W. Liposome coated with low molecular weight chitosan and its potential use in ocular drug delivery. International Journal of Pharmaceutics. 2009;379(1-2):131-138.

    Not in our library10.1016/j.ijpharm.2009.06.020

  11. 11.

    Ding X, Alani WG, Robinson JR, Troy DB. extended-release and targeted drug delivery systems. Remington: The Science and Practice of Pharmacy. 2005.

    Not in our library

  12. 12.

    Jesorka A, Orwar O. Liposomes: technologies and analytical applications. Annual Review of Analytical Chemistry. 2008;1(1):801-832.

    Not in our library10.1146/annurev.anchem.1.031207.112747

  13. 13.

    Lian T, Ho RJY. Trends and developments in liposome drug delivery systems. Journal of Pharmaceutical Sciences. 2001;90(6):667-680.

    Not in our library10.1002/jps.1023

  14. 14.

    Niesman MR. The use of liposomes as drug carriers in ophthalmology. Critical Reviews in Therapeutic Drug Carrier Systems. 1992;9(1):1-38.

    Not in our library

  15. 15.

    Papahadjopoulos D, Jacobson K, Nir S, Isac T. Phase transitions in phospholipid vesicles. Fluorescence polarization and permeability measurements concerning the effect of temperature and cholesterol. Biochimica et Biophysica Acta. 1973;311(3):330-348.

    Not in our library10.1016/0005-2736(73)90314-3

  16. 16.

    Guy RH, Hadgraft J, Taylor MJ, Kellaway IW. Release of non-electrolytes from liposomes. Journal of Pharmacy and Pharmacology. 1983;35(1):12-14.

    Not in our library10.1111/j.2042-7158.1983.tb04254.x

  17. 17.

    Tsukada K, Ueda S, Okada R. Preparation of liposome-encapsulated anti-tumor drugs: relationship between lipophilicity of drugs and in vitro drug release. Chemical and Pharmaceutical Bulletin. 1984;32(5):1929-1935.

    Not in our library

  18. 18.

    Zeng L, Wu X. Modeling the sustained release of lipophilic drugs from liposomes. Applied Physics Letters. 2010;97(7):3 pages.

    Not in our library

  19. 19.

    Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug Discovery. 2005;4(2):145-160.

    Not in our library10.1038/nrd1632

  20. 20.

    Bonacucina G, Cespi M, Misici-Falzi M, Palmieri GF. Colloidal soft matter as drug delivery system. Journal of Pharmaceutical Sciences. 2009;98(1):1-42.

    Not in our library10.1002/jps.21423

  21. 21.

    Ruiz-Moreno JM, Montero JA, Arias L, et al. Photodynamic therapy in subfoveal and juxtafoveal idiopathic and postinflammatory choroidal neovascularization. Acta Ophthalmologica Scandinavica. 2006;84(6):743-748.

    Not in our library10.1111/j.1600-0420.2006.00691.x

  22. 22.

    Lazzeri S, Figus M, Di Bartolo E, Rizzo S, Nardi M. Verteporfin photodynamic therapy for retinal hemangioblastoma associated with Von Hippel-Lindau Disease in a 9-year-old child.

    Not in our library10.1111/j.1442-9071.2010.02428.x

  23. 23.

    Sachdeva R, Dadgostar H, Kaiser PK, Sears JE, Singh AD. Verteporfin photodynamic therapy of six eyes with retinal capillary haemangioma. Acta Ophthalmologica. 2010;88(8):e334-e340.

    Not in our library10.1111/j.1755-3768.2010.02008.x

  24. 24.

    Chakravdrthy U, Soubrane G, Bandello F, et al. Evolving European guidance on the medical management of neovascular age related macular degeneration. British Journal of Ophthalmology. 2006;90(9):1188-1196.

    Not in our library10.1136/bjo.2005.082255

  25. 25.

    Rostaporfin: PhotoPoint SnET2, purlytin, Sn(IV) etiopurpurin, SnET2, tin ethyl etiopurpurin. Drugs in R and D. 2004;5(1):58-61.

    Not in our library10.2165/00126839-200405010-00013

  26. 26.

    Shen Y, Tu J. Preparation and ocular pharmacokinetics of ganciclovir liposomes. AAPS Journal. 2007;9(3):E371-E377.

    Not in our library10.1208/aapsj0903044

  27. 27.

    Hosny KM. Ciprofloxacin as ocular liposomal hydrogel. AAPS PharmSciTech. 2010;11(1):241-246.

    Not in our library10.1208/s12249-009-9373-4

  28. 28.

    Danion A, Arsenault I, Vermette P. Antibacterial activity of contact lenses bearing surface-immobilized layers of intact liposomes loaded with levofloxacin. Journal of Pharmaceutical Sciences. 2007;96(9):2350-2363.

    Not in our library10.1002/jps.20871

  29. 29.

    Cortesi R, Argnani R, Esposito E, et al. Cationic liposomes as potential carriers for ocular administration of peptides with anti-herpetic activity. International Journal of Pharmaceutics. 2006;317(1):90-100.

    Not in our library10.1016/j.ijpharm.2006.02.050

  30. 30.

    Hathout RM, Mansour S, Mortada ND, Guinedi AS. Liposomes as an ocular delivery system for acetazolamide: in vitro and in vivo studies. AAPS PharmSciTech. 2007;8(1, article 1).

    Not in our library10.1208/pt0804080

  31. 31.

    Zhang R, He R, Qian J, Guo J, Xue K, Yuan YF. Treatment of experimental autoimmune uveoretinitis with intravitreal injection of tacrolimus (FK506) encapsulated in liposomes. Investigative Ophthalmology & Visual Science. 2010;51(7):3575-3582.

    Not in our library10.1167/iovs.09-4373

  32. 32.

    Camelo S, Lajavardi L, Bochot A, et al. Ocular and systemic bio-distribution of rhodamine-conjugated liposomes loaded with VIP injected into the vitreous of Lewis rats. Molecular Vision. 2007;13:2263-2274.

    Not in our library

  33. 33.

    Fukushima A, Ozaki A, Ishida W, van Rooijen N, Fukata K, Ueno H. Suppression of macrophage infiltration into the conjunctiva by clodronate liposomes in experimental immune-mediated blepharoconjunctivitis. Cell Biology International. 2005;29(4):277-286.

    Not in our library10.1016/j.cellbi.2004.12.011

  34. 34.

    Kawakami S, Harada A, Sakanaka K, et al. In vivo gene transfection via intravitreal injection of cationic liposome/plasmid DNA complexes in rabbits. International Journal of Pharmaceutics. 2004;278(2):255-262.

    Not in our library10.1016/j.ijpharm.2004.03.013

  35. 35.

    Peeters L, Sanders NN, Braeckmans K, et al. Vitreous: a barrier to nonviral ocular gene therapy. Investigative Ophthalmology and Visual Science. 2005;46(10):3553-3561.

    Not in our library10.1167/iovs.05-0165

  36. 36.

    Schaeffer HE, Krohn DL. Liposomes in topical drug delivery. Investigative Ophthalmology and Visual Science. 1982;22(2):220-227.

    Not in our library

  37. 37.

    Singh K, Mezei M. Liposomal ophthalmic drug delivery system. I. Triamcinolone acetonide. International Journal of Pharmaceutics. 1983;16(3):339-344.

    Not in our library

  38. 38.

    Singh K, Mezei M. Liposomal ophthalmic drug delivery system. II. Dihydrostreptomycin sulfate. International Journal of Pharmaceutics. 1984;19(3):263-269.

    Not in our library

  39. 39.

    Fitzgerald P, Hadgraft J, Wilson CG. A gamma scintigraphic evaluation of the precorneal residence of liposomal formulations in the rabbit. Journal of Pharmacy and Pharmacology. 1987;39(6):487-490.

    Not in our library10.1111/j.2042-7158.1987.tb03428.x

  40. 40.

    Aiba S. Studies on chitosan: 4. Lysozymic hydrolysis of partially N-acetylated chitosans. International Journal of Biological Macromolecules. 1992;14(4):225-228.

    Not in our library10.1016/s0141-8130(05)80032-7

All 82 references

Cited by papers we hold 2

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.